Cargando…

Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema

BACKGROUND: The purpose of this study is to assess the effectiveness of topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (intravitreal dexamethasone and peribulbar triamcinolone) in treating pseudophakic macular edema (PME). METHODS: Retrospective study of 33 eyes. Variables...

Descripción completa

Detalles Bibliográficos
Autores principales: Obis, Javier, Arias, Luis, Lorenzo, Daniel, Padron-Perez, Noel, Garcia-Bru, Pere, Cobos, Estefania, Morwani, Rahul, Caminal, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570006/
https://www.ncbi.nlm.nih.gov/pubmed/34740334
http://dx.doi.org/10.1186/s12886-021-02132-w
_version_ 1784594755699605504
author Obis, Javier
Arias, Luis
Lorenzo, Daniel
Padron-Perez, Noel
Garcia-Bru, Pere
Cobos, Estefania
Morwani, Rahul
Caminal, Jose
author_facet Obis, Javier
Arias, Luis
Lorenzo, Daniel
Padron-Perez, Noel
Garcia-Bru, Pere
Cobos, Estefania
Morwani, Rahul
Caminal, Jose
author_sort Obis, Javier
collection PubMed
description BACKGROUND: The purpose of this study is to assess the effectiveness of topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (intravitreal dexamethasone and peribulbar triamcinolone) in treating pseudophakic macular edema (PME). METHODS: Retrospective study of 33 eyes. Variables included best corrected visual acuity (BCVA; logMAR scale) and central retinal thickness (CRT) and central choroidal thickness (CCT) assessed with swept-source OCT. All patients were initially prescribed topical NSAIDs and reevaluated after 2 months. If improvement in BCVA or CRT was noted, topical NSAIDs were continued until resolution. If no improvement was observed at 2 months or subsequent visits, intravitreal dexamethasone implant was performed. Patients who refused intravitreal treatment were offered peribulbar triamcinolone. RESULTS: After treatment with topical NSAIDs for a median of 2 months, BCVA increased significantly from 0.5 to 0.3 while CRT decreased significantly from 435 to 316 μm. PME resolved in 19 of the 33 eyes (57.6%). Of the 14 recalcitrant cases, 13 were treated with corticosteroids. Of these 13 cases, 9 (69.2%) resolved. BCVA increased non-significantly from 0.7 to 0.4. CRT and CCT decreased significantly from 492 to 317 μm and from 204 to 182 μm respectively. CONCLUSIONS: The overall success rate of the treatment algorithm was greater than 80%, a remarkable finding considering that no randomized study has yet been conducted to determine the optimal therapeutic protocol for PME. This is the first study to evaluate choroidal thickness in PME using SS-OCT, which could play a key role in its pathophysiology and provide useful information to improve the management of PME.
format Online
Article
Text
id pubmed-8570006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85700062021-11-08 Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema Obis, Javier Arias, Luis Lorenzo, Daniel Padron-Perez, Noel Garcia-Bru, Pere Cobos, Estefania Morwani, Rahul Caminal, Jose BMC Ophthalmol Research BACKGROUND: The purpose of this study is to assess the effectiveness of topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (intravitreal dexamethasone and peribulbar triamcinolone) in treating pseudophakic macular edema (PME). METHODS: Retrospective study of 33 eyes. Variables included best corrected visual acuity (BCVA; logMAR scale) and central retinal thickness (CRT) and central choroidal thickness (CCT) assessed with swept-source OCT. All patients were initially prescribed topical NSAIDs and reevaluated after 2 months. If improvement in BCVA or CRT was noted, topical NSAIDs were continued until resolution. If no improvement was observed at 2 months or subsequent visits, intravitreal dexamethasone implant was performed. Patients who refused intravitreal treatment were offered peribulbar triamcinolone. RESULTS: After treatment with topical NSAIDs for a median of 2 months, BCVA increased significantly from 0.5 to 0.3 while CRT decreased significantly from 435 to 316 μm. PME resolved in 19 of the 33 eyes (57.6%). Of the 14 recalcitrant cases, 13 were treated with corticosteroids. Of these 13 cases, 9 (69.2%) resolved. BCVA increased non-significantly from 0.7 to 0.4. CRT and CCT decreased significantly from 492 to 317 μm and from 204 to 182 μm respectively. CONCLUSIONS: The overall success rate of the treatment algorithm was greater than 80%, a remarkable finding considering that no randomized study has yet been conducted to determine the optimal therapeutic protocol for PME. This is the first study to evaluate choroidal thickness in PME using SS-OCT, which could play a key role in its pathophysiology and provide useful information to improve the management of PME. BioMed Central 2021-11-05 /pmc/articles/PMC8570006/ /pubmed/34740334 http://dx.doi.org/10.1186/s12886-021-02132-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Obis, Javier
Arias, Luis
Lorenzo, Daniel
Padron-Perez, Noel
Garcia-Bru, Pere
Cobos, Estefania
Morwani, Rahul
Caminal, Jose
Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
title Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
title_full Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
title_fullStr Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
title_full_unstemmed Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
title_short Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
title_sort topical nsaids, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570006/
https://www.ncbi.nlm.nih.gov/pubmed/34740334
http://dx.doi.org/10.1186/s12886-021-02132-w
work_keys_str_mv AT obisjavier topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema
AT ariasluis topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema
AT lorenzodaniel topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema
AT padronpereznoel topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema
AT garciabrupere topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema
AT cobosestefania topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema
AT morwanirahul topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema
AT caminaljose topicalnsaidsintravitrealdexamethasoneandperibulbartriamcinoloneforpseudophakicmacularedema